2021

Professional development Vacancies
2021
Regarding amendments to the instructions for medical use of medicinal products containing rituximab (rituximab)

Taking into account the report of the Pharmacovigilance Risk Assessment Committee (PRAC) based on the analysis of Periodic Safety Update Reports (PSURs) for…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing regorafenib (regorafenib)

Following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing panitumumab (panitumumab)

Taking into account the report of the Pharmacovigilance Risk Assessment Committee (PRAC) based on the analysis of Periodic Safety Update Reports (PSURs) for…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing methotrexate

Following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), recommendations were issued on updating the package inserts. Taking…

Read more
Regarding amendments to the package inserts for medicinal products containing Iberis amara L., planta tota recens/Angelica archangelica L., radix/Matricaria recutita L., flos/Carum carvi L., fructus/Silybum marianum (L.) Gaertn., fructus/Melissa officinalis L., folium/Mentha piperita L., folium/Chelidonium majus L., herba/Glycyrrhiza glabra L., radix

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products that…

Read more
Report on the assessment of the risk of thrombosis in combination with thrombocytopenia after Vaxzevria vaccination and recommendations on administering the second dose of the vaccine.

On 16 September 2021, a meeting of the Committee for Medicinal Products for Human Use (CHMP) was held and the Risk Assessment Report was published…

Read more
Regarding amendments to the package leaflet of medicinal products containing posaconazole

Taking into account the report of the Pharmacovigilance Risk Assessment Committee (PRAC) based on the analysis of Periodic Safety Update Reports (PSURs) for…

Read more
Regarding amendments to the package leaflet of medicinal products containing vortioxetine

Taking into account the report of the Pharmacovigilance Risk Assessment Committee (PRAC) based on the analysis of Periodic Safety Update Reports (PSURs) for…

Read more
Updated safety information on COVID-19 vaccines

ACCORDING TO EMA, on 08 September 2021, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency published updated information on…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing ibrutinib (ibrutinib)

Taking into account the report of the Pharmacovigilance Risk Assessment Committee (PRAC) based on the analysis of Periodic Safety Update Reports (PSURs) for…

Read more